Rapid changes in human immunodeficiency virus type 1 rna load and appearance of drug-resistant virus populations in persons treated with lamivudine (3tc)

Journal of Infectious Diseases

Volumn 171, Issue 6, 1995, Pages 1411-1419

  Schuurman, Rob ^a,b,c,d,e   Nijhuis, Monique ^a,b,c,d,e   Van Leeuwen, Remko ^a,b,c,d   Schipper, Pauline ^a,b,c,d,e   De Jong, Dorien ^a,b,c,d,e   Collis, Phil ^a,b,c,d   Danner, Sven A ^a,b,c,d   Mulder, John ^a,b,c,d   Loveday, Clive ^a,b,c,d   Christopherson, Cindy ^a,b,c,d   Kwok, Shirley ^a,b,c,d   Sninsky, John ^a,b,c,d   Boucher, Charles A B ^a,b,c,d,e  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b GLAXOSMITHKLINE   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d ROCHE MOLECULAR SYSTEMS   (United States)

^e UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

3 [(4,7 DICHLORO 2 BENZOXAZOLYLMETHYL)AMINO] 5 ETHYL 6 METHYL 2(1H) PYRIDONE; ALPHA INTERFERON; AMINO ACID; ANTIGEN P24; CD4 ANTIGEN; ISOLEUCINE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VALINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CODON; CYTOFLUOROMETRY; DRUG RESISTANCE; ENZYME IMMUNOASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SERUM;

CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, MICROBIAL; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMAN; LAMIVUDINE; LONGITUDINAL STUDIES; MALE; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; SUPPORT, NON-U.S. GOV'T; ZALCITABINE;

EID: 0029024089     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/171.6.1411     Document Type: Article

References (27)

1. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989;243:1731-4.
2. Rooke R., Tremblay M, Soudeyns H, et al. Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy. AIDS 1989:3:411-5.
3. Fitzgibbon JE, Howell RM, Haberzettl CA, Sperber SJ, Gocke DJ, Dubin DT. Human immunodeficiency virus type I poI gene mutations which cause decreased susceptibility to 2',3'-dideoxycytidine. Antimicrob Agents Chemother 1992;36:153-7.
4. Saag MS. Emini EA. Laskin OL, et al. L-697 6W. A short-term clinical evaluation of L-697,661. a non-nucleoside inhibitor of HIV-1 reverse transcriptase. N Engl J Med 1993;329:1065-72.
5. St. Clair MH, Martin JL., Tudor-Williams G, et al. Resistance to ddl and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991;253:1557-9.
6. de Jong MD, Loewenthal M, Boucher CAB, et al. Alternating nevira pine and zidovudine treatment of human immunodeficiency virus type 1 -infected persons does not prolong nevirapine activity. J Infect Dis 1994;169:1346-50.
7. Richman DD, Havlir D., Corbeil J. et al. Nevirapine resistance mutations of human immunodeficiency virus type I selected during therapy. J Virol 1994;68:1660-6.
8. Gao Q, Gu Z, Hiscott J. Dionne G, Wainberg MA. Generation of drug-resistant variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother 1993;37:130-3.
9. Schinazi RF, Lloyd RM Jr. Nguyen MH, et al. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother 1993;37:875-81.
10. Tisdale M, Kemp SD. Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 1993;90:5653-6.
11. Boucher CAB, Cammack N, Schipper P, Schuurman R, Rouse PL, Cameron JM. High level resistance to (-) enantiomeric 2'-deoxy-3'- thiacytidine (3TC) in vitro is due to one amino acid substitution in the catalytic site of HIV-1 reverse transcriptase. Antimicrob Agents Chemother 1993;37:2231-4.
12. Kozal MJ, Shafer RW, Winters MA, Katzenstein DA, Merigan TC. A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J Infect Dis 1993;167:526-32.
13. Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L. Kwok S. A rapid and simple PCR assay for quantification of HIV RNA: application to acute retroviral infection. J Clin Microbiol 1994;32:292-300.
14. Kaye S, Loveday C., Tedder RS. A microtiter format point mutation assay: application to the detection of drug resistance in human immunodeficiency virus type-1 infected patients treated with zidovudine. J Med Virol 1992;37:241-6.
15. van Leeuwen R, Katlama C, Kitchen V, et al. Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection a phase I/II study. J Infect Dis 1995; 171:1166-71.
16. Boom R, Sol CJA, Salimans MMM, Jansen CL, Wertheim-van Dillen PME, Noordaa van der J. A rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990;28:495-503.
17. Lin HJ, Myers LE, Yen-Lieberman B, et al. Multicenter evaluation of quantitation methods for plasma human immunodeficiency virus type 1 RNA. J Infect Dis 1994;170:553-62.
18. Syvanen AC, Aalto-Setala K, Harja L, Kantula K, Soderlun H. A primer-guided nucleotide incorporation assay in the genotyping of apolipoprotein E. Genomics 1990;8:684-92.
19. Kellam P. Larder BA. Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother 1994;38:23-30.
20. Roos MTL, Miedema F., Eeftinck Schattenkerk JKM, et al. Cellular and humoral immunity in various cohorts of male homosexuals in relation to infection with human immunodeficiency virus. Neth J Med 1989;34:132-41.
21. Hughes MD, Stein DS. Gundacker HM, Valentine FT, Phair JP, Vol- berding PA. Within-subject variation in CD4 lymphocyte count in asymptomatic human immunodeficiency virus infection: implications for patient monitoring. J Infect Dis 1994;169:28-36.
22. Schuurman R. Keulen W. Modified protocol for DNA sequence analysis using Sequenase 2.0. Biotechniques 1990; 11:185.
23. Gao Q., Gu Z, Parniak MA. et al. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'- dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine. Antimi- crob Agents Chemother 1993;37:1390-2.
24. Ji J, Loeb LA. Fidelity of HIV-1 reverse transcriptase copying a hyper variable region of the HIV-1 env gene. Virology 1994;199:323-30.
25. Wakefield JK, Jablonski SA, Morrow CD. In vitro enzymatic activity of human immunodeficiency virus type 1 reverse transcriptase mutants in the highly conserved YMDD amino acid motif correlates with the infectious potential of the proviral genome. J Virol 1992;66:6806-12.
26. Larder BA, Kemp SD, Purifoy DJM. Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity. Proc Natl Acad Sci USA 1989;86:4803-7.
27. Boyer PL, Ferris AL, Hughes SH. Cassette mutagenesis of the reverse transcriptase of human immunodeficiency virus type i. J Virol 1992;66:1031-9.